Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProTCE-PSMA (ShangHai Hengrui Pharma)
- Development stage
- Preclinical
- Lead developer
- HenRui Pharmaceuticals
01
Overview
ProTCE-PSMA (ShangHai Hengrui Pharma): sourced facts only. name: "And a PSMA/CD3 prodrug (ProTCE-PSMA) was designed with the building blocks including a high affinity VHH antibody for PSMA, a proprietary CD3 binder, a CD3 masking peptide, a cleavable linker, and anti-HSA sdAb for PK switch." [DOI:10.1158/1538-7445.am2026-lb261]; target: "And a PSMA/CD3 prodrug (ProTCE-PSMA) was designed with the building blocks including a high affinity VHH antibody for PSMA, a proprietary CD3 binder, a CD3 masking peptide, a cleavable linker, and anti-HSA sdAb for PK switch." [DOI:10.1158/1538-7445.am2026-lb261]; developer: "ShangHai Hengrui Pharmaceuticals Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2026-lb261]; modality: "And a PSMA/CD3 prodrug (ProTCE-PSMA) was designed with the building blocks including a high affinity VHH antibody for PSMA, a proprietary CD3 binder, a CD3 masking peptide, a cleavable linker, and anti-HSA sdAb for PK switch." [DOI:10.1158/1538-7445.am2026-lb261]; stage: "These characteristics enabled ProTCE-PSMA to demonstrate superior efficacy in CDX models with various levels of PSMA expression, compared with HRP358." [DOI:10.1158/1538-7445.am2026-lb261]
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on ProTCE-PSMA (ShangHai Hengrui Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProTCE-PSMA (ShangHai Hengrui Pharma).